Neonc Technologies Holdings, Inc. (NTHI)
NeOnc Technologies develops drug candidates for brain cancers, including NEO100 and NEO212, which are still in clinical trials. It last closed at $3.15 on Nov 20, down 9.48% on the day. The next earnings report for NTHI is expected around Fri, Apr 2, 2027, after the close. For the quarter ended Sep 2026, NTHI reported EPS of -$0.28 on revenue of $0. Over its last 6 reports the stock moved an average of 8.7% the session after earnings. Over the last 12 months NTHI insiders bought $2.0M of stock on the open market and sold $0, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From NTHI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on NTHI
Technical AnalysisPrices may be delayed
The stock is 16% below its 20 day and 4% below its 50 day average. It is 61% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 42). The nearest support is the swing low (Aug 13) at $3.13, and the nearest resistance the Pivot at $3.27.
| RSI (14) | 41.90 | Middle of its range | Neutral |
| MACD | 0.21 | Below its signal line | Bearish |
| Stochastic | 27.1 | Middle of its range | Neutral |
| ADX (14) | 36.0 | Trending up | |
| Williams %R | -90.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -45.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −9.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.54 | Typical daily range, 17.1% of price |
| RSI (14) | 42.45 | Middle of its range | Neutral |
| MACD | -0.55 | Above its signal line | Bullish |
| Stochastic | 40.6 | Middle of its range | Neutral |
| ADX (14) | 15.2 | No clear trend | |
| Williams %R | -80.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | 18.0 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −14.4% | Change over 10 sessions | Bearish |
| ATR (14) | $1.13 | Typical daily range, 36.0% of price |
What happened before
See how NTHI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options FlowPrices may be delayed
90DNo whale options trades in NTHI in the last 90 days.
NTHI Institutional Ownership
Full report →- ▲12 buying vs 5 selling
- ▲Held by funds +6.2 pts
- ▲Funds holding +6
- ▲Superinvestors: 1 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 27 | 21 | +28.6% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 17.1% | 10.9% | +6.2 pts |
| New / increased | 6 / 6 | 1 / 10 | +9.1% |
| Reduced / sold out | 5 / 0 | 4 / 8 | −58.3% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
NTHI Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 13 | Amir F HeshmatpourCEO, President | Buy | 30,000 | $5.02 | $151K |
| Nov 11 | Amir F HeshmatpourCEO, President | Buy | 70,000 | $4.21 | $295K |
| Nov 10 | Thomas C ChenCmo | Buy | 5,016 | $3.99 | $20K |
| Nov 9 | Amir F HeshmatpourCEO, President | Buy | 10,000 | $3.86 | $39K |
| Nov 6 | Amir F HeshmatpourCEO, President | Buy | 70,000 | $3.29 | $231K |
| Sep 15 | Amir F HeshmatpourCEO, President | Buy | 50,000 | $3.50 | $175K |
From SEC Form 4 filings by NTHI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NTHI is in one of them and how their past NTHI trades turned out.
NTHI News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered NTHI in an article yet. Here's the latest on the wider market.
- NeOnc CEO Amir Heshmatpour’s 2026 Open-Market Share Purchases Exceed $1.5 Million
- Neonc Technologies Holdings, Inc.: Regulation FD disclosure
- NeOnc CEO Amir Heshmatpour Adds 80,000 Shares in Open-Market Purchases
- NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
- NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
- NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi
About Neonc Technologies Holdings
NeOnc Technologies develops drugs for cancers that start in the brain or spread there, including glioblastoma, meningioma and brain metastases from lung, breast and skin cancers. Its lead candidates are NEO100, a purified form of perillyl alcohol given by nasal spray, and NEO212, an oral drug that combines temozolomide with perillyl alcohol. The company has no approved products yet and is testing its candidates in trials with patients who have brain tumors. It is based in Calabasas, California.
- Headquarters
- Calabasas, CA
